Impact of Untreated Obstructive Sleep Apnea on Left and Right Ventricular Myocardial Function and Effects of CPAP Therapy

Christoph Hammerstingl*, Robert Schueler*, Martin Wiesen, Diana Momcilovic, Stefan Pabst, Georg Nickenig, Dirk Skowasch

University of Bonn, Department of Internal Medicine II, Cardiology, Pulmonology and Angiology, Bonn, Germany

Abstract

Background: Obstructive sleep apnea (OSA) has deteriorating effect on LV function, whereas its impact on RV function is controversial. We aimed to determine the effect of OSA and continuous positive airway pressure (CPAP) treatment on left and right ventricular (LV, RV) function using transthoracic echocardiography (TTE) and 2 dimensional speckle tracking (2D ST) analysis of RV deformation capability.

Methods and Results: 82 patients with OSA and need for CPAP therapy were prospectively enrolled and underwent TTE at study inclusion and after 6 months of follow up (FU). Multivariate regression analysis revealed an independent association between baseline apical right ventricular longitudinal strain (RV-Sl), BMI and the severity of OSA (apical RV-Sl: P = 0.0002, BMI: P = 0.02). After CPAP therapy, LV functional parameters (LVEF: P < 0.0001, LV performance index: P = 0.03, stroke volume: P = 0.042), and apical RV-Sl (P = 0.001) improved significantly. The effect of CPAP therapy was related to severity of OSA (LVEF: AHI 5–14: 66.4 ± 8.8%, 68.5 ± 10.6% [P = ns]; AHI 15–30: 59.8 ± 7.7%, 68.6 ± 9.3% [P = 0.002]; AHI > 30: 54.1 ± 12.4%, 68.2 ± 13.6% [P < 0.0001]; apical RV-Sl: AHI 5–14: −17.3 ± 8.7%, −16.0 ± 10.8% [P = ns], AHI 15–30: −9.8 ± 6.0%, −15.4 ± 10.9% [P = 0.028], AHI > 30: −6.3 ± 5.7%, −17.9 ± 11.2% [P < 0.0001]).

Conclusions: OSA seems to have deteriorating effect on LV and RV function. We found a beneficial effect of CPAP on LV and RV functional parameters predominately in patients with severe OSA. 2D speckle tracking might be of value to determine early changes in global and regional right ventricular function.

Introduction

Obstructive sleep apnea (OSA) is a frequent sleep-related breathing disorder with an incidence of 5–20% in the middle-aged population in Europe and Northern America [1,2]. Pathophysiological consequences of OSA are increased sympathetic activity, hypoxia, hypercapnia, increased left ventricular afterload and acute arterial hypertension [3]. Recent studies have shown that OSA is an independent risk factor for cardiovascular mortality and morbidity [4]. In clinical practice, it might be difficult to evaluate the effects of OSA on myocardial function because many of the risk factors for OSA, such as obesity, male gender, and age may contribute to both, OSA and cardiovascular disease [5].

Using conventional Doppler echocardiography, several studies have recently reported the detrimental effect of untreated severe OSA on systolic and diastolic left ventricular (LV) function [6,7]. The effect of OSA on right ventricular (RV) function and its reversibility under effective therapy is not well investigated. Furthermore, the usefulness of two dimensional speckle tracking (2D ST), a novel ultrasound based technique for the determination of regional and global myocardial deformation properties [8], to visualize OSA related changes in RV function is unclear.

The aims of this prospective cohort study were (i) to investigate the impact of OSA and its severity on left and right ventricular function measured with echocardiography and two-dimensional strain analysis and (ii) to determine the effect of effective OSA therapy on measurable left/right ventricular functional parameters.

Methods

Patients and Follow Up

Patients admitted between May 2009 and December 2009 to the Department of Pneumology of our hospital, for OSA screening and initiation of continuous positive airway pressure therapy (CPAP) were included in the study. Clinical follow-up examinations were scheduled after 1 and 6 months for the adjustment of CPAP therapy. Echocardiography for the detection of CPAP related changes in LV/RV function was planned at study initiation and after 6 months (±14 days) of follow up.
Table 1. Demographic and echocardiographic characteristics of the study group.

| All patients at baseline (n=82) | All patients at 6 months FU (mean ± SD) (n=82) | Group 1 AHI 5–14 (n=29) | Group 2 AHI 15–30 (n=24) | Group 3 AHI>30 (n=29) | p-value |
|-------------------------------|-----------------------------------------------|-------------------------|--------------------------|------------------------|---------|
| Age [years]                   | 63.3±11.5                                     | 61.8±13.0               | 66.3±10.5                | 62.5±10.7              | ns      |
| Male gender                   | 52 (63.4%)                                    | 52 (63.4%)              | 21 (72.4%)               | 13 (54.1%)             | 17 (58.6%) ns |
| BMI [kg/m²]                   | 30.7±5.5                                      | 30.7±6.4                | 28.9±4.9                | 30.4±4.5               | 32.9±6.3 0.02 |
| AHI [n/h]                     | 31.4±26.8                                     | 5.6±7.1                 | 9.0±2.8                 | 22.0±4.4               | 61.7±22.7 <0.0001 |
| ODI                           | 22.7±23.0                                     | 7.3±10.1                | 8.4±8.7                 | 19.2±10.2              | 40.5±28.7 <0.0001 |
| ESS                           | 10.0±5.4                                      | 7.5±4.5                 | 8.5±4.1                 | 9.4±4.9                | 13.6±4.9 0.03 |
| Hypertension                  | 44 (53.6%)                                    | 44 (53.6%)              | 13 (44.8%)              | 15 (62.5%)             | 16 (53.1%) ns |
| CHF                           | 16 (19.5%)                                    | 16 (19.5%)              | 4 (13.8%)               | 4 (16.6%)              | 7 (24.1%) ns |
| Diabetes mellitus             | 10 (12.2%)                                    | 10 (12.2%)              | 1 (3.4%)                | 4 (16.6%)              | 5 (17.2%) ns |
| History of stroke             | 4 (4.9%)                                      | 4 (4.9%)                | 2 (6.8%)                | 2 (8.3%)               | 0 (0%) ns |
| CAD                           | 11 (13.4%)                                    | 11 (13.4%)              | 3 (10.0%)               | 5 (20.8%)              | 3 (10.3%) ns |
| Smoking                       | 30 (36.6%)                                    | 30 (36.6%)              | 10 (34.5%)              | 7 (29.1%)              | 12 (41.3%) ns |
| HLP                           | 30 (36.6%)                                    | 30 (36.6%)              | 9 (31.0%)               | 12 (50%)               | 9 (31%) ns |
| Medication                    |                                              |                         |                         |                        |         |
| Aspirin                       | 25 (30.5%)                                    | 25 (30.5%)              | 7 (24.1%)               | 9 (37.5%)              | 9 (31%) ns |
| Beta blocker                  | 25 (30.5%)                                    | 25 (30.5%)              | 8 (27.6%)               | 7 (29.2%)              | 10 (34.5%) ns |
| ACEI/ARB                      | 25 (30.5%)                                    | 25 (30.5%)              | 6 (20.7%)               | 9 (37.5%)              | 10 (34.5%) ns |
| Diuretics                     | 26 (31.7%)                                    | 26 (31.7%)              | 8 (27.6%)               | 10 (41.7%)             | 8 (27.6%) ns |
| Statin                        | 18 (22%)                                      | 18 (22%)                | 6 (20.7%)               | 7 (29.2%)              | 5 (17.2%) ns |
| Oral anticoagulant            | 5 (6.1%)                                      | 5 (6.1%)                | 3 (10.6%)               | 3 (12.5%)              | 1 (3.4%) ns |
| Echocardiography              |                                              |                         |                         |                        |         |
| LV EF [%]                     | 60.7±8.4                                      | 63.2±7.2^               | 65.0±6.9                | 59.5±6.9               | 57.5±5.6 <0.0001 |
| sPAP [mmHg]                   | 16.9±11.2                                     | 16.7±11.6               | 18.6±12.3               | 15.7±10.1              | 16.4±11.0 ns |
| TAPSE [mm]                    | 66.0±23.9                                     | 67.7±21.9               | 66.0±23.9               | 68.7±23.7              | 62.6±21.5 ns |
| MV e/a’                      | 0.8±0.9                                       | 0.8±0.9                 | 0.8±0.9                 | 0.9±0.3                | 0.9±0.4 ns |
| LV MPI                        | 0.4±0.2                                       | 0.4±0.2                 | 0.4±0.2                 | 0.4±0.2                | 0.5±0.1 ns |
| e/a’                          | 11.0±6.2                                      | 10.1±3.6                | 9.9±2.7                 | 10.3±3.2               | 12.7±9.5 ns |
| RV MPI                        | 0.4±0.3                                       | 0.4±0.2                 | 0.3±0.2                 | 0.4±0.4                | 0.3±0.3 ns |
| TDI TKS [m/s]                 | 0.1±0.02                                      | 0.4±1.9                 | 0.1±0.02                | 0.1±0.02               | 0.1±0.03 ns |
| 2D global RV-SI [%]           | −16.9±7.5                                     | −17.6±8.6               | −21.5±6.3               | −14.3±5.3              | −14.5±8.2 <0.0001 |
| 2D apical RV-SI [%]           | −11.3±8.4                                     | −15.0±6.8^              | −17.3±8.7               | −9.8±6.0               | −6.3±5.7 <0.0001 |
| 2D medial RV-SI [%]           | −16.9±8.2                                     | −15.6±8.0               | −19.8±5.6               | −14.9±6.8              | −15.7±10.7 ns |
| 2D basal RV-SI [%]            | −22.7±13.3                                    | −21.5±12.8              | −27.4±13.6              | −18.2±8.7              | −21.6±14.9 0.03 |

1Significance of changes when comparing baseline and follow up measurements <0.05; 2D RV-SI, two dimensional right ventricular longitudinal strain; ACEI, angiotensin converting enzyme inhibitors; AHI, apnea hypopnea index; ARBl, angiotensin receptor blocker; CAD, coronary artery disease; CHF, chronic heart failure; BMI, body mass index; e/a’, early/atrial; ESS, Epworth sleepiness scale; HLP, hyperlipoproteinemia; IVSd, diastolic interventricular septum thickness; LVd, left ventricular ejection fraction; LV/RV MPI, left ventricular/right ventricular myocardial performance index; MV e/a’, mitral velocity early/atrial; ns, not statistically significant; ODI, oxygen desaturation index; SD, standard deviation; sPAP, systolic pulmonary artery pressure; SV, stroke volume; TAPSE, tricuspid annular plane systolic excursion; TDI TKS, tricuspid annular systolic tissue Doppler velocity. doi:10.1371/journal.pone.0076352.t001

According to current research we hypothesized that OSA has a deteriorating effect on LV function (defined as significant decrease in LV EF) and that after a 6 months CPAP therapy the impairment could in part be ameliorated. Furthermore we assumed RV function to be likewise impaired by OSA (defined as significant decrease in RV strain) and likewise ameliorated by CPAP. Study endpoints were (i) prevalence of echocardiographically detectable pathologic myocardial left and right ventricular functional parameters in patients undergoing OSA screening before initiation of CPAP therapy, and (ii) the evaluation of changes in measurable LV/RV functional parameters after OSA therapy with CPAP.

All patients had to provide written informed consent prior to study inclusion; the study was approved by local ethics committee and was in accordance with the Declaration of Helsinki. Exclusion criteria were presence of predominant central sleep apnea (CSA),
non compliance to CPAP (<4 h use/night) and AHI<5. However, the number of patients not compliant with CPAP or AHI<5 and willing to comply with the study protocol was too small to serve as a meaningful control group.

**OSA Diagnosis and Initiation of CPAP Therapy**

All patients underwent an overnight polysomnographic study at baseline (SOMNOlab, Weinmann, Hamburg) and polygraphy controls after one week and 6 months (Embletta, Medcare Flaga HI, Reykjavik).

On the day of the overnight sleep study, classic baseline characteristics were assessed (Table 1). Epworth sleepiness scale (ESS) was obtained to assess daytime sleepiness. Thoracoabdominal movements were measured by calibrated respiratory inductance plethysmograph and oxyhemoglobin saturation was obtained by fingertip oximetry. The mean lowest oxyhemoglobin saturation (SaO2) during sleep was calculated by averaging the lowest SaO2 for each 30-s episode during sleep. OSA was defined as an absence of airflow for at least 10 s and hypopneas as a >50% reduction in airflow from the baseline level for at least 10 s with a 3% decrease in oxygen saturation, during which there were paradoxical thoracoabdominal movements. The diagnosis of OSA at baseline was made by standard attended polysomnography (SOMNOlab, Weinmann, Hamburg) device: The electroencephalogram, electrooculogram, and electromyogram of chin muscles, as well as ECG were simultaneously recorded; oral-nasal airflow (with thermal and pressure sensing device), thoraco-abdominal respiratory movements, body position, snoring, and oximetry were also obtained. Then, the patients underwent a titration of the allocated CPAP device during a second overnight, in-laboratory, attended polysomnography. Airway pressure was manually modulated from 4 cm H2O to the effective pressure, with a maximum of 12 cm H2O. The appropriate fixed pressure was chosen as the pressure abolishing or significantly decreasing obstructive events. Patients underwent polygraphy controls after one week and 6 months (Embletta, Medcare Flaga HI, Reykjavik). According to current guidelines, subjects with more than five obstructive apneas and hypopneas were considered as suffering from OSA. In addition, central apneas and snoring were measured. Analysis and interpretation of sleep study data were performed without knowing the patient’s clinical condition.

CPAP was recommended to all patients who had more than 30 episodes of apnea or hypopnea per hour of sleep. CPAP was also recommended if the AHI was between 5 and 30 and the patient complained of severe daytime sleepiness that interfered with daily activities.

Compliance with CPAP was checked by readings of the built-in time counter of the patient’s device. Only those patients for whom
calculation of the time of use per night gave a value higher than four hours were considered compliant with. The adherence to CPAP in the whole patient cohort was 4.8±1.4 hours per night, whereas the time of used CPAP showed to be 6.5±1.1 hours per night in the study cohort. Effective OSA therapy was defined as ≥25% drop in AHI or AHI<5 after 6 months of CPAP treatment and mean reduction in Epworth Sleepiness Score of 3 points [9,10].

![Figure 2. Comparative receiver operating characteristic (ROC) curves analysis of BMI and apical 2D RV-SI for the identification of patients with an AHI>30. 2D RV-SI, two dimensional right ventricular strain; AHI, apnea hypopnea index; P, significance of difference between the two curves.](image)

doi:10.1371/journal.pone.0076352.g002

![Figure 3. Boxplot - Development of left ventricular ejection fraction after CPAP according to AHI groups. AHI, apnea hypopnea index; LVEF, left ventricular ejection fraction; ns, not significant.](image)

doi:10.1371/journal.pone.0076352.g003
Transthoracic Echocardiography

Each patient had a complete standardized two-dimensional transthoracic echocardiography study for the determination of LV/RV functional parameters and dimensions according to the recommendations of the American Society of Echocardiography [11,12] using a commercially available ultrasound scanner (Vivid 7, General Electric Medical Health, Waukesha, Wisconsin, USA; iE 33, Philips Medical Systems, Koninklijke N.V.) with a 2.5-MHz phased-array transducer. Echocardiographic views, including apical four- and two-chamber views (4CV, 2CV), with the patient in the left lateral decubitus position, were obtained in two-dimensional and colour tissue Doppler imaging (TDI) modes. Mitral inflow velocities were recorded by standard pulsed-wave Doppler at the tips of the mitral valve leaflets in an apical 4CV. TDI derived systolic and diastolic velocities were obtained from the septal mitral and lateral tricuspid valve annuli.

LV and RV myocardial performance indices (MPI) were assessed, following the original approach of Tei and colleagues and were therefore calculated as the ratio between the sum of times of the isovolumetric periods and ejection time for the right ventricle [13,14]. Echo systolic pulmonary artery pressure (sPAP) was estimated by measuring the peak systolic tricuspid regurgitant velocity from continuous wave Doppler if applicable. Values of sPAP are provided in mmHg, without addition of central venous pressure.

For the determination of longitudinal RV contractility, tricuspid annular systolic excursion (TAPSE) was measured in the four-chamber view [15] as well as systolic tricuspid annulus velocities with TDI. All echocardiographic studies were performed by one single experienced cardiologist. Interpretation of the echo data was performed by echo experienced cardiologists, who were blinded to the clinical information when analysing the data.

2D-speckle-tracking Analysis of Right Ventricular Deformation Capabilities

Two cine loops from apical four chamber view were digitized and stored in an echocardiographic imaging server (NCELEA, Philips Medical Systems, Koninklijke N.V.). Offline 2D-ST-analyses of the gray scale images obtained by 2D echocardiography were done using commercially available software (TomTec Imaging Systems GmbH, Unterschleissheim, Germany). The endocardium of the free RV wall was manually traced starting from the lateral tricuspid annulus to RV apex, and was tracked by the 2D strain software along the border throughout two cardiac cycles. Accuracy of border tracking was manually verified and adjusted if needed. The free right ventricular wall was segmented visually in a basal, midventricular and apical segment. For the determination of OSA related changes in RV contractility, we compared global as well as regional RV functional parameters of the RV free wall.

Statistical Analysis

Exploratory data analysis was performed and no adjustment was made for multiple tests. Two-tailed P-values were calculated and considered to be significant if ranging below 0.05. Continuous

Figure 4. Boxplot - Development of apical RV-Sl after CPAP according to AHI groups. 2D RV-Si, two dimensional right ventricular strain; AHI, apnea hypopnea index; ns, not significant. doi:10.1371/journal.pone.0076352.g004
data were expressed as mean values ± standard deviation. For comparisons between groups normalcy tests were done for each parameter. Continuous variables were tested for differences with the Kruskal-Wallis or One-way ANOVA test, when comparing more than two groups. For categorical variables, the Chi square or Fisher’s exact test were used for further analysis. Demographic and clinical characteristics of patients undergoing polysomnography were therefore excluded from the final analysis. 82 consecutive patients with polysomnographic proven OSA were included in the study.

Clinical and baseline characteristics of these patients are presented in Table 1. Overall, patients presented significant levels of daytime sleepiness (ESS 10.07 ± 5.42) and severe OSA (AHI 30.75 ± 5.5 n/h). Body mass index (BMI, 31.45 ± 26.83 kg/m²) correlated significantly to the severity of the sleep disordered breathing (P = 0.0007) (Figure 1a).

Patients were divided into three groups according to the severity of OSA following the recommendation of the American Academy of Sleep Medicine guidelines [9,16]: group 1: AHI 5–14, n = 29; group 2: AHI 15–30, n = 24; group 3: AHI>30, n = 29).

Patients in group 3 were more often obese, had significantly lower left ventricular ejection fraction and stroke volume. Values for global, apical and basal longitudinal strain were lower as compared to patients with moderate or low AHI score (Table 1).

Comparison of Baseline Demographic and Echocardiographic Data According to the Severity of OSA

Severity of OSA at baseline was significantly correlated with a decrease in measurable systolic LV function (P = 0.005) (Figure 1b), whereas parameters for the determination of LV diastolic function were not significantly altered in patients with severe OSA.

Global and regional RV deformation properties derived from 2D RV longitudinal strain were significantly reduced in patients with higher AHI and correlated well to the severity of OSA (Figure 1c,d, Table 1). Conventional right functional parameters such as TAPSE, and right ventricular performance index (RV MPI) were not significantly decreased in patients with increasing AHI (Table 1).

Table 2. Echocardiographic and clinical parameters before and after 6 months of CPAP treatment.

| Parameter | Baseline (n = 82) | After CPAP (n = 82) | p value |
|-----------|------------------|-------------------|---------|
| AHI [n/h] | 31.4 ± 26.8      | 5.6 ± 7.1         | <0.0001 |
| ESS       | 10.0 ± 5.4       | 7.5 ± 4.5         | <0.0001 |
| LV EF [%] | 60.7 ± 8.4       | 63.2 ± 7.2        | 0.001   |
| sPAP [mmHg]| 16.9 ± 11.2      | 16.7 ± 11.6       | ns      |
| IVSd [cm] | 1.3 ± 0.2        | 1.3 ± 0.4         | ns      |
| SV [ml]   | 66.0 ± 23.9      | 67.7 ± 21.9       | ns      |
| MV e’/a’  | 0.8 ± 0.9        | 0.8 ± 0.4         | ns      |
| LV MPI    | 0.4 ± 0.2        | 0.4 ± 0.2         | ns      |
| e’        | 11.0 ± 6.2       | 10.1 ± 3.6        | ns      |
| RV MPI    | 0.4 ± 0.3        | 0.4 ± 0.2         | ns      |
| TAPSE     | 24.8 ± 5.9       | 24.3 ± 5.9        | ns      |
| 2D global RV-Sl [%] | −16.9 ± 7.5 | −17.6 ± 8.5 | ns |
| 2D apical RV-Sl [%] | −11.3 ± 8.4 | −15.0 ± 6.8 | 0.001 |
| 2D medial RV-Sl [%] | −16.9 ± 8.2 | −15.6 ± 8.0 | ns |
| 2D basal RV-Sl [%] | −22.7 ± 13.3 | −21.5 ± 12.8 | ns |

Table 3. Intraobserver and interobserver reproducibility of apical and global 2D RV-Sl assed by 2 dimensional speckle tracking imaging.

| Parameter          | Mean difference ± SD | ICC   | p-value |
|--------------------|----------------------|-------|---------|
| Intraobserver      |                      |       |         |
| 2D global RV-Sl    | 1.8 ± 7.5            | 0.88  | 0.007   |
| 2D apical RV-Sl    | 1.5 ± 1.1            | 0.96  | 0.001   |
| 2D mid RV-Sl       | 2.0 ± 1.2            | 0.85  | 0.01    |
| 2D basal RV-Sl     | 1.9 ± 1.5            | 0.87  | 0.009   |

| Parameter          | Mean difference ± SD | ICC   | p-value |
|--------------------|----------------------|-------|---------|
| Interoobserver     |                      |       |         |
| 2D global RV-Sl    | 2.0 ± 8.9            | 0.82  | 0.02    |
| 2D apical RV-Sl    | 2.8 ± 3.1            | 0.92  | 0.01    |
| 2D mid RV-Sl       | 3.0 ± 2.1            | 0.79  | 0.03    |
| 2D basal RV-Sl     | 2.5 ± 1.2            | 0.80  | 0.03    |

2D RV-Sl, two dimensional right ventricular longitudinal strain; ICC, intraclass correlation coefficient; SD, standard deviation.

doi:10.1371/journal.pone.0076352.t003

doi:10.1371/journal.pone.0076352.t002

doi:10.1371/journal.pone.0076352.t001

doi:10.1371/journal.pone.0076352.t000
Cardiovascular co-morbidities or clinical risk factors, such as hypertension, coronary artery disease, or diabetes were not associated with the rate of apnea hypopnea episodes.

After multivariate stepwise regression analysis of all echocardiographic parameters and baseline demographics (Table S1), only apical RV-Sl and BMI were independently associated with severe OSA (apical RV-Sl, \( P = 0.0002 \), BMI, \( p = 0.02 \)). Severe OSA was defined as AHI > 30, according to definitions by the American Academy of Sleep Medicine (9). These variables entered comparative receiver-operated-characteristic-curve (ROC) analysis (Figure 2), which identified apical RV-Sl (sensitivity: 51.5%, specificity: 72.2%, cut-off: 18.4) to have a stronger association with AHI > 30 than BMI (sensitivity: 46.4%, specificity: 74.1%, cut-off: 21.5).

Additionally, oxygen desaturation index (ODI) was significantly correlated with clinical and echocardiographic baseline data: \( r = 0.72 \), \( P < 0.0001 \) for correlation with AHI, \( r = 0.4 \) (\( P < 0.0001 \)) for global 2D RV-Sl, \( r = 0.36 \) (\( P = 0.001 \)) for apical 2D RV-Sl, \( r = 0.35 \) (\( P = 0.001 \)) for BMI, \( r = -0.17 \) (\( P = 0.13 \)) for LV EF. These correlations were similar to correlations with AHI.

Discussion

The main findings of our study are as follows:

(i) OSA has a detrimental effect on LV and RV function, which increases with severity of disease. (ii) This effect is in part reversible under effective OSA therapy and (iii) patients with severe OSA and associated myocardial dysfunction benefit most from CPAP therapy.

To the best of our knowledge, this is one of the first studies to examine the impact of severe OSA on global and regional right ventricular function as determined with 2D ST and the effect of CPAP therapy on measurable right ventricular functional parameters.

Severity of OSA and LV/RV Dysfunction

The impact of obstructive sleep apnea on left and right ventricular function and structure is controversial. Theoretically, OSA relevantly influences RV and LV hemodynamics by an increase of pulmonary artery pressure during apnea episodes [17,18]. Severe hypoxemia, hypercapnia and acidosis lead to sympathetic activation and therefore to sympathetic mediated vasoconstriction during apnea episodes increasing systolic blood pressure, vascular shear stress and consequently the risk for myocardial infarction [19,20]. However, evidence from previous studies assessing right ventricular function in OSA patients is inconsistent with a wide range of OSA dependent right ventricular alterations which were detected in 0–70% of patients included [21–23].

In the Framingham Heart study, the effect of sleep-disordered breathing on right heart structure and function was examined by Guidry and colleagues. They demonstrated that diameters of the RV cavities of the right heart and LV systolic function were not significantly diverging between two groups of patients with different severity of sleep disordered breathing [24]. On the other hand, Romero-Coral and colleagues showed that OSA leads to impaired right and left ventricular function determined with MPI in 85 OSA patients undergoing their first overnight polysomnography [25]. Sanner and colleagues reported a significant correlation between AHI and right ventricular ejection fraction measured with radionuclide ventriculography in 107 patients [26]. Recently, Colish and colleagues found right ventricular and atrial diameters positively influenced by 12 months of CPAP therapy in a cohort of 47 OSA patients [27].

The impact of OSA on systolic and diastolic LV function has been largely addressed by several authors [28,29]. The positive effect of CPAP therapy on left ventricular function was shown by Shivalkar et al. They proved that interventricular septum thickness, left ventricular stroke volume and right ventricular tissue Doppler systolic velocity increase after effective CPAP therapy [30]. Butt and colleagues were able to prove a positive effect of CPAP on LV function using 2-dimensional echocardiography, tissue Doppler imaging, and 3-dimensional echocardiography in subjects with moderate-severe OSA, compared to a matched patient cohort without OSA [31].

This complies with our findings of structural and functional cardiac alterations in patients with sleep related breathing disorder and the favorable effects of CPAP.

The results of a recently published study by Altekin and colleagues are, also, in line with our findings, that there is a strong correlation of RV strain and the severity of OSA. In this study RV strain was even able to detect RV dysfunction in a subclinical phase of RV function deterioration [32].

The partially discrepant findings from the cited studies concerning RV functional parameters might be due to the fact that follow up time as well as definition of OSA were not consistently defined. Furthermore, the determination of RV function is not standardized. Indirect parameters for deteriorated RV function such as RV diameter or wall diameters might not be eligible to monitor early and subtle changes in RV function.

BMI was significantly related to AHI frequency and was the only demographic parameter shown to be independent associated with the severity of OSA. Nevertheless, the correlation between apical 2D RV-Sl and AHI frequency was stronger as confirmed with comparative ROC curve analysis. This emphasizes...
the independent and important relation of apical RV impairment and severity of OSA.

2D Strain and RV Function

2D strain imaging has been established as assessment of regional left and right ventricular function and offers a good correlation with right ventricular ejection fraction as well [33,34]. It is known to be of excellent value to evaluate LV regional and global function. 2D ST has a good inter- and intra-observer agreement, is well correlated to MRI and highly reproducible [35]. Speckle-tracking analysis derived 2 dimensional strain values are independent from the angle of insonation [36], and therefore offer reasonable advantages over TDI for the determination of regional wall abnormalities [37,38].

Furthermore, 2D strain derived parameters have been found superior to conventional echocardiographic parameters for identification of patients with severe pathological alterations in RV function such as arrhythmogenic right ventricular dysplasia (ARVD) [39] and for the monitoring of medical treatment of severe pulmonary hypertension (PH) [40].

In our study on patients with different stages of OSA, we found a significant correlation of regional and global RV strain parameters with the severity of OSA and of note, a relevant increase of RV deformation capabilities after CPAP therapy. Our data indicates that apical RV function alteration might be a sensitive parameter to detect early and even subclinical deterioration in RV function.

These findings are in line with the results from Fernández-Frier et al. who used CMR for RV function imaging in a cohort of 192 patients with different stages of pulmonary hypertension (PH). The author and colleagues found that basal RV ejection fraction (RVEF) did not differ between patients with mild or moderate PH. However, they showed that patients with moderate PH had significantly lower apical RVEF, with an apical fraction (RVEF) did not differ between patients with mild or severe PH. The author and colleagues found that basal RV ejection fraction did not improve even after CPAP therapy. Our study shows that the use of 2D ST in patients with severe PH, they found apical longitudinal strain most predictive for adverse outcome in those patients [42].

Clinical Impact

Since OSA is closely related to left and right ventricular dysfunction which improves with effective CPAP therapy, we suggest an early start of CPAP therapy in all patients with relevant OSA to prevent permanent impairment of the left and right ventricular function and structure.

Limitations

The study is limited by its not randomized, not blinded and single side character. Our sleep clinic cohort may not reflect the findings in the general community because of the limited number of patients. Our sleep clinic cohort may not reflect the findings in the general community because of the limited number of patients. Whilst significant cardiovascular co morbidities were present at baseline in our study cohort we do not fully exclude that changes in RV or LV function could have been mediated by an indirect effect of CPAP therapy on these co morbidities. The observational design of the study does not allow for this concern to be addressed. Furthermore, there are many other confounding factors that might alter global and regional RV function in the general population.

Our conclusion applies therefore specifically to a pre-selected population with proven OSA.

Conclusion

OSA seems to have deteriorating impact on left and right ventricular function. After 6 months of therapy, we found a beneficial effect of CPAP on LV and RV functional parameters which was pronounced in patients with severe OSA. 2D speckle tracking might be of value to determine early changes in global and regional right ventricular function.

Supporting Information

Table S1 Multivariate stepwise regression analysis of all echocardiographic parameters and baseline demographics.

(DOCX)

Acknowledgments

We thank Karin Springmann for her excellent technical support.

Author Contributions

Conceived and designed the experiments: RS CH GN DS. Performed the experiments: RS CH MW. Analyzed the data: RS CH DM SP. Contributed reagents/materials/analysis tools: RS CH DS GN. Wrote the paper: RS CH DS.
embolism: a study using tricuspid annular motion. Echocardiography 27: 286–93.

16. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. (1999) Sleep 22: 667–89.

17. Usui Y, Takata Y, Inoue Y, Tomiyama H, Kurohame S, et al. (2013) A. Severe obstructive sleep apnea impairs left ventricular diastolic function in non-obese men. Sleep Med 14: 155–9.

18. Chan JY, Li AM, Au CT, Lo AF, Ng SK, et al. (2009) Cardiac remodelling and cardiac biomarkers, echocardiography, and cardiac MRI. Chest 141: 674–81.

19. Usui Y, Villarraga HR, Orban M, Bruce CJ, Presman GS, et al. (2010) Changes in left and right ventricular mechanics during the Mueller maneuver in healthy adults: a possible mechanism for abnormal cardiac function in patients with obstructive sleep apnea. Circ Cardiovasc Imaging 3: 262–9.

20. Hammerstingl C, Schueler R, Wiesen M, Momcilovic D, Pabst S, et al. (2012) Effects of untreated obstructive sleep apnea on left and right ventricular myocardial function. Int J Cardiol 135: 853–9.

21. Butter M, Driessen GJ, Schouten JS, Meert R, Roman MJ, et al. (2008) Left ventricular morphology and systolic function in sleep-disordered breathing: the Sleep Heart Health Study. Circulation117: 2509–607.

22. Kim SH, Cho GV, Shin C, Lim HE, Kim YH, et al. (2008) Impact of obstructive sleep apnea on left ventricular diastolic function. Am J Cardiol 101: 1663–8.

23. Bradley TD (1992) Right and left ventricular functional impairment and sleep apnea. Clin Chest Med 13: 459–79.

24. Guidry UC, Mendes LA, Evans JC, Levy D, O'Connor GT, et al. (2001) Echocardiographic features of the right heart in sleep-disordered breathing: the Framingham Heart Study. Am J Respir Crit Care Med164: 933–8.

25. Romero-Corral A, Somers VK, Pellikka PA, Olson EJ, Bailey KR, et al. (2007) Decreased right and left ventricular myocardial performance in obstructive sleep apnea. Chest 132: 1863–70.

26. Sanner BM, Konermann M, Sturm A, Muller HJ, Zidek W (1997) Right ventricular hypertrophy detected by echocardiography in patients with newly diagnosed obstructive sleep apnea. Chest 106: 347–50.

27. (32) Altekin RE, Karakas MS, Yalikoglu A, Ozal D, Ozbudak O, et al. (2012) Determination of right ventricular dysfunction using the speckle tracking echocardiography method in patients with obstructive sleep apnea. Cardiol J 19: 130–9.

28. Junutur, R, Giurca S, La GA, Viale S, Ginghina C, et al. (2010) The echocardiographic assessment of the right ventricle: what to do in 2010? Eur J Echocardiogr 11: 81–96.

29. D’hooge J, Heimdal A, Jamal F, Kukulski T, Bijnen B, et al. (2000) Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. Eur J Echocardiogr 1: 154–70.

30. Shivalkar B, Van de HC, Kerremans M, Rinkevich D, Verbraecken J, et al. (2006) Obstructive sleep apnea syndrome: more insights on structural and functional cardiac alterations, and the effects of treatment with continuous positive airway pressure. J Am Coll Cardiol 47: 1433–9.

31. Tske AJ, Cox MG, De Boeck BW, Oeverendans PA, Hauer RN, et al. (2009) Echocardiographic tissue deformation imaging quantifies abnormal regional right ventricular function in arrhythmogenic right ventricular dysplasia/ cardiomyopathy. J Am Soc Echocardiogr 22: 920–7.

32. Malick W, et al. (2011) Apical right ventricular dysfunction in patients with obstructive sleep apnea. Cardiol J 19: 130–9.

33. Weidemann F, Kowalski M, D’hooge J, Bijnen B, Sutherland GR (2001) Doppler myocardial imaging. A new tool to assess regional inhomogeneity in cardiac function. Basic Res Cardiol 96: 595–605.

34. D’hooge J, Wouters PF, Leather HA, Claus P, et al. (2005) Experimental validation of a new ultrasound method for the simultaneous assessment of radial and longitudinal myocardial deformation independent of insonation angle. Circulation 112: 2157–62.

35. Langeland S, D’hooge J, Wouters PF, Leather HA, Claus P, et al. (2005) Echocardiographic assessment of the right ventricle: what to do in 2010? Eur J Echocardiogr 11: 81–96.

36. Weidemann F, Koswaldi M, D’hooge J, Bijnen B, Sutherland GR (2001) Experimental validation of a new ultrasound method for the simultaneous assessment of radial and longitudinal myocardial deformation independent of insonation angle. Circulation 112: 2157–62.

37. D’hooge J, Wouters PF, Leather HA, Claus P, et al. (2005) Echocardiographic tissue deformation imaging quantifies abnormal regional right ventricular function in arrhythmogenic right ventricular dysplasia/ cardiomyopathy. J Am Soc Echocardiogr 22: 920–7.

38. Malick W, et al. (2011) Apical right ventricular dysfunction in patients with obstructive sleep apnea. Cardiol J 19: 130–9.

39. Fernandez-Frieza A, Garcia-Alvarez A, Gusman G, Bagherieannejad-Esfahani F, Malek W, et al. (2011) Apical right ventricular dysfunction in patients with pulmonary hypertension demonstrated with magnetic resonance. Heart 97: 1250–6.

40. Lopez-Candales A, Rajagopalan N, Gulyasy B, Edelman K, Bazaz R (2009) Differential strain and velocity generation along the right ventricular free wall in pulmonary hypertension. Can J Cardiol 25: e73–e77.